Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion
Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion
PR Newswire
GALWAY, Ireland and BRAINTREE, Mass., Sept. 9, 2026
GALWAY, Ireland and BRAINTREE, Mass., Sept. 9, 2026 /PRNewswire/ -- Neurent Medical, the pioneer behind the NEUROMARK® System for the treatment of chronic rhinitis, today announced that it has secured a €25 million growth debt financing facility from Claret Capital Partners.
The financing will support the continued commercial expansion of NEUROMARK®, accelerate investment in sales and marketing initiatives, strengthen the company's balance sheet, and provide additional capital to support future growth opportunities.
The financing follows Neurent Medical's successful €62.5 million Series C financing completed earlier this year, further reinforcing the company's position as a leader in minimally invasive treatments for chronic inflammatory sinonasal diseases.
Brian Shields, CEO of Neurent Medical said:
"This financing represents another important milestone for Neurent Medical as we continue to scale our commercial operations and expand patient access to NEUROMARK. We are delighted to deepen our relationship with Claret Capital Partners, whose continued support reflects confidence in our technology, clinical evidence, commercial progress and long-term vision. The facility provides significant financial flexibility while allowing us to continue executing our growth strategy with minimal dilution to shareholders."
Daniel Mallon, Principal at Claret Capital Partners comments:
"Neurent Medical has demonstrated exceptional progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis. We are pleased to further support the company as it continues its commercial expansion and works to improve outcomes for millions of patients suffering from chronic rhinitis."
About Neurent Medical
Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK® System utilizes proprietary impedance-controlled radiofrequency technology to target hyperactive posterior nasal nerves, offering durable relief from chronic rhinitis symptoms. The company is headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts.
For more information visit www.neurentmedical.com.
About Claret Capital Partners
Claret Capital Partners is Europe's largest independent growth debt fund manager. Since 2013, the firm has invested over €1.5bn through its funds, supporting more than 210 companies across the technology, life sciences and impact sectors. Its team has been active in investing into European companies for over 25 years, providing innovative debt solutions that help entrepreneurs and their investors grow their companies while minimising dilution.
For more information visit www.claret-capital.com
Claret Capital Partners Limited (company registered number 12516001) is authorised and regulated by the Financial Conduct Authority (FRN 993228).
SOURCE Neurent Medical
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
Why This Vanguard ETF Is One of the Best
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States